PharmaEngine has announced the initiation of the Phase I human clinical trial of its new drug PEP07 for solid tumors, with the first patient receiving the drug.
PharmaEngine stated that the company received approval from the Taiwan Food and Drug Administration in September 2023 to conduct the Phase I human clinical trial of PEP07 for solid tumors in Taiwan. PEP07 is an orally available small molecule inhibitor of checkpoint kinase 1 (CHK1), targeting the DNA damage response (DDR) pathway. It exhibits high selectivity, potency, and the ability to penetrate the blood-brain barrier. PEP07 has demonstrated both single-agent activity and potential in combination with other standard therapies in preclinical tumor models. Today marks the dosing of the first patient in the Phase I human clinical trial for solid tumors being conducted in Taiwan.
Resource (Mandarin):
